Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPiyatida ChumnumsiriwathKNKiran NaqviSGShawn P. Griffin

Discussion

Loading...

Member takes

Overview

Observational study shows blinatumomab maintenance improves overall survival in adult B-ALL post-AHSCT, suggesting effective relapse management strategies.

Key Points

  • The study aimed to evaluate the impact of adding blinatumomab to a conditioning regimen before and after AHSCT in adult B-ALL patients.
  • Included 31 adult B-ALL patients undergoing AHSCT with variants of a fludarabine-melphalan regimen.
  • Used low-dose TBI or thiotepa based on CNS involvement, with pre- and post-AHSCT blinatumomab maintenance in high-risk patients.
  • Followed patients for a median of 700 days to assess survival outcomes and relapses.
  • The 1-year overall survival rates were 74.4%, with notable improvement in high-risk patients receiving maintenance.
  • None of the CNS leukemia patients experienced relapse post-AHSCT with the intensified regimen.
  • Blinatumomab maintenance resulted in a significant increase in progression-free survival compared to no maintenance.

Cite This Study

Chumnumsiriwath et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e52bhttps://doi.org/10.1182/blood-2025-2520
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia2025
  2. 2Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  3. 3Blinatumomab Maintenance Therapy Following Bone Marrow Transplantation for Early Relapsed Pediatric B-cell Precursor Acute Lymphoblastic Leukemia and Analysis of Lymphocyte Subset Changes2024 · 1 citations
  4. 4Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations
  5. 5Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024